Wedbush Reiterates Outperform on Denali Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Denali Therapeutics (NASDAQ:DNLI) and maintained a $31 price target.

February 28, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico reiterates an Outperform rating on Denali Therapeutics and maintains a $31 price target.
The reiteration of an Outperform rating and the maintenance of a $31 price target by a reputable analyst like Laura Chico from Wedbush could positively influence investor sentiment towards DNLI. This endorsement reaffirms the analyst's confidence in the company's prospects, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100